Popis: |
This study analyzed the role of vasohibin-1 (VASH1) in human cancer outcomes. Relevant original studies on VASH1 expression in cancers were searched from PubMed, ClinicalKey, and Cochrane Library databases. A meta-analysis was performed to evaluate the role of VASH1 in clinicopathological characteristics and overall survival (OS) of patients with tumors. Statistical analysis was performed using the RevMan v. 5.3 software. Our meta-analysis results showed that patients with high VASH1 expression experienced a significantly poor prognosis with a hazard ratio (HR) of 1.69 (95% confidence interval [CI], 1.16- 2.46, P = 0.006) for OS, and an HR of 2.21 (95% CI, 1.32-3.68, P = 0.003) for progression-free survival. Furthermore, the high expression of VASH1 was significantly relevant to advanced tumor node metastasis stages. Thus, VASH1 is a potential biomarker to predict unfavorable clinical outcomes, serving as a potential tumor treatment target. |